<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095210</url>
  </required_header>
  <id_info>
    <org_study_id>MA1021</org_study_id>
    <nct_id>NCT02095210</nct_id>
  </id_info>
  <brief_title>HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025</brief_title>
  <official_title>Phase 1 Study, Evaluating HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dorte Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-labeled, exploratory, single center study. Patients with a big primary breast&#xD;
      cancer (≥ 3 cm) or metastatic first line, routinely have their HER2-expression determined by&#xD;
      biopsy. Patients having a HER2-positive tumor will be recruited to the study. A [18F]FDG&#xD;
      PET/ceCT scan is performed for the measurement of uptake in the tumour and diagnosis of&#xD;
      possible metastases. Each subject will receive a single injection of the investigational&#xD;
      product [68Ga]ABY-025, followed by measurement of uptake in the tumour or metastases and in&#xD;
      normal organs. The investigations will be repeated after HER2 directed therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">August 13, 2014</completion_date>
  <primary_completion_date type="Actual">August 13, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the uptake distribution of the HER2-binding imaging agent [68Ga]ABY-025 by PET imaging in breast cancer patients with biopsy-identified HER2 expression</measure>
    <time_frame>28 days from last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess concordance of [68Ga]ABY-025 uptake with [18F]FDG PET uptake before and after HER2 therapy</measure>
    <time_frame>within 14 days before study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. pharmacokinetics of [68Ga]ABY-025 and whole-body dosimetry of [68Ga]ABY-025</measure>
    <time_frame>6 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>[68Ga]ABY-025 PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiolabeled [68Ga]ABY-025</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiolabeled [68Ga]ABY-025</intervention_name>
    <description>Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.</description>
    <arm_group_label>[68Ga]ABY-025 PET imaging</arm_group_label>
    <other_name>tracer for HER2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is &gt; 18 years of age&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of breast adenocarcinoma ≥ 3 cm&#xD;
             determined by ultrasound, or locally advanced breast cancer (LABC: T3-4NxMx or&#xD;
             TxN2-3Mx)&#xD;
&#xD;
          3. HER2-positiv breast cancer first recurrence&#xD;
&#xD;
          4. HER2-positiv breast cancer primary metastatic&#xD;
&#xD;
          5. HER2 status has been determined on biopsy material from the primary tumour and found&#xD;
             to be HER2-positive, defined as a DAKO HercepTest™ score of 3+ or else 2+ and FISH&#xD;
             positive&#xD;
&#xD;
          6. [18F]FDG PET/ceCT performed within 7 days before administration of IMP&#xD;
&#xD;
          7. ECOG performance status of =&lt; 2&#xD;
&#xD;
          8. Hematological, liver and renal function test results within the following limits:&#xD;
&#xD;
               -  White blood cell count: &gt; 2.0 x 10^9/L&#xD;
&#xD;
               -  Haemoglobin: &gt; 5.0 mmol/L&#xD;
&#xD;
               -  Platelets: &gt; 50.0 x 10^9/L&#xD;
&#xD;
               -  ALT, ALP: =&lt; 3 times Upper Limit of Normal&#xD;
&#xD;
               -  Bilirubin =&lt; 2.0 times Upper Limit of Normal&#xD;
&#xD;
               -  Serum creatinine: Within Normal Limits&#xD;
&#xD;
          9. A negative pregnancy test (serum beta-HCG) at screening for all subjects of&#xD;
             childbearing potential&#xD;
&#xD;
         10. Subject is capable to undergo the diagnostic investigations to be performed in the&#xD;
             study&#xD;
&#xD;
         11. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Known hypersensitivity to Dotarem® 2. Active known autoimmune disease or history of&#xD;
             autoimmune disease 3. Active serious infection according to investigator evaluation 4.&#xD;
             Known HIV positive or chronically active hepatitis B or C 5. Administration of other&#xD;
             investigational medicinal product within 30 days of screening 6. Pregnant or&#xD;
             breast-feeding 7. Women capable of childbearing not using a sufficient non-hormonal&#xD;
             method of birth control 8. Other primary malignancies (including primary brain tumors)&#xD;
             within the last 5 years before inclusion, with exception of sufficiently treated in&#xD;
             situ carcinoma of the cervix, squamous carcinoma of the skin or sufficiently&#xD;
             controlled limited basal cell carcinoma of the skin 9. Signs of any other disease,&#xD;
             metabolic or psychological dysfunction, findings at physical examination or laboratory&#xD;
             findings, which give reasonable suspicion of a disease or condition that would&#xD;
             contraindicate use of the IMP, could influence the patient's compliance with the study&#xD;
             routines or involves an increased risk for treatment-related complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malgorzata K Tuxen, MD, P.hd.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev University Hospital, Oncology Department</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Dorte Nielsen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PET scan</keyword>
  <keyword>HER2</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

